Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nanjing Biosion Out-licenses Global Rights for Trop2 mAb to OBI Pharma

publication date: Dec 16, 2021

Biosion, a Nanjing-Delaware immunoncology company, out-licensed global rights for its anti-Trop2 humanized monoclonal antibody to Taiwan's OBI Pharma. OBI will conduct preclinical and clinical development plus commercialization of BSI04702 as an antibody drug conjugate along with other products. BSI04702 was created using Biosion's proprietary SynTracerTM HT-endocytosis platform, a high-throughput endocytosis screening application that identifies antibodies with high internalization rates. OBI Pharma will make upfront, milestone and royalty payments, though specific details were not disclosed. More details....

Stock Symbol: (TWO: 4174)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.